India’s market regulator, the Securities and Exchange Board of India (SEBI), has confirmed enforcement action against pharmaceutical company Par Drugs and Chemicals Ltd following findings related to regulatory non-compliance. The decision reflects SEBI’s ongoing efforts to strengthen transparency and accountability in India’s capital markets. According to officials, the order addresses alleged irregularities concerning disclosure norms and corporate governance obligations.